VEGFA and renal cell carcinoma: For example, in a study on renal cell carcinoma (RCC) patients treated with PD-L1 or combinational therapy of PD-L1 + anti-VEGF-A, the TMB and the tumor neoantigen burden (TNB) did not correlate with the response to therapy.